BC
VRDN icon

BIT Capital’s Viridian Therapeutics VRDN Stock Holding History

BIT Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,005
Closed -$130K – 138
2025
Q3 		$130K Buy
6,005
+2,472
+70% +$44.6K ﹤0.01% 90
2025
Q2 		$49.4K Sell
3,533
-68,147
-95% -$925K ﹤0.01% 88
2025
Q1 		$966K Sell
71,680
-214,274
-75% -$3.65M 0.08% 59
2024
Q4 		$5.48M Buy
285,954
+201,808
+240% +$4.39M 0.44% 36
2024
Q3 		$1.91M Sell
84,146
-61,410
-42% -$1M 0.18% 49
2024
Q2 		$1.89M Hold
145,556
– – 0.15% 57
2024
Q1 		$2.55M Buy
145,556
+138,963
+2,108% +$2.69M 0.19% 58
2023
Q4 		$144K Buy
+6,593
New +$104K 0.01% 81

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BIT Capital's VRDN Position: Q4 2025 in Review

BIT Capital sold out of Viridian Therapeutics (VRDN) in Q4 2025, closing a stake of 6,005 shares — an estimated $130K sold.

BIT Capital first reported a position in VRDN in Q4 2023 and held it in 8 quarters. The position peaked at $5.48M in Q4 2024. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • BIT Capital reported no remaining Viridian Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BIT Capital sold 6,005 Viridian Therapeutics shares in Q4 2025, an estimated $130K.
  • BIT Capital first reported a position in Viridian Therapeutics in Q4 2023 and held it in 8 quarters.
  • BIT Capital's Viridian Therapeutics position peaked at $5.48M in Q4 2024.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on BIT Capital's 13F filing for Q4 2025, filed 11 Feb 2026.